ライフサイエンスコーパス: IL-1RAcP

1 type I (IL-1RI) and IL-1R accessory protein (IL-1RAcP).

2 designated IL-1 receptor accessory protein (IL-1RAcP).

3 6R.IL-36alpha binary complex, which recruits IL-1RAcP.

4 ary complex with IL-36R, which then recruits IL-1RAcP.

5 signaling by a decrease of interaction with IL-1RAcP.

6 raction of IL-1Rrp2 ECD with the co-receptor IL-1RAcP.

7 ated co-immunoprecipitation of IL-1Rrp2 with IL-1RAcP.

8 ceptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP.

9 uction can be inhibited by dominant-negative IL-1RAcP.

10 -1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP.

11 s dependent on the expression of IL-1RI, not IL-1RAcP.

12 e was no change in the surface expression of IL-1RAcP.

13 ide 4 recognized intact IL-1RAcP and soluble IL-1RAcP.

14 tion of a complex containing both IL-1RI and IL-1RAcP.

15 to this complex through its association with IL-1RAcP.

16 cromolar affinity but do not detectably bind IL-1RAcP.

17 form a complex with IL-1R accessory protein (IL-1RAcP), a signaling receptor subunit that is also a m

18 However, these IL-1RAcP Abs had no effect on the activity of human or m

19 rface plasmon resonance (SPR), we found that IL-1RAcP also does not bind IL-36R when no agonist is pr

20 Steady state levels of mRNA for IL-1RAcP and IL-1RI in D10S cells showed a similar patte

21 Anti-peptide 4 recognized intact IL-1RAcP and soluble IL-1RAcP.

22 Antibodies directed against IL-1RAcP and transfection of cytoplasmically deleted IL-

23 pression of IL-1 receptor accessory protein (IL-1RAcp) and IL-1 type I receptor (IL-1RI), but not IL-

24 tor and the IL-1 receptor accessory protein (IL-1RAcP) as a receptor partner.

25 and transfection of cytoplasmically deleted IL-1RAcP both blocked activation of the pathway leading

26 In the presence of IL-36alpha, however, IL-1RAcP bound IL-36R strongly.

27 The implications of this shared usage of IL-1RAcP by IL-1(alpha and beta) and IL-33 are discussed

28 upt the interaction of MyD88 with the IL-1RI/IL-1RAcP complex, we analyzed the involvement of MyD88 i

29 pendent of MyD88 association with the IL-1RI/IL-1RAcP complex.

30 ended on a MyD88 interaction with the IL-1RI/IL-1RAcP complex.

31 the IL-1RI/IL-1 receptor accessory protein (IL-1RAcP) complex through homomeric Toll/IL-1 receptor (

32 ot measure the binding affinity of IL-36R to IL-1RAcP directly, so we engineered a fragment crystalli

33 tudies have shown that IL-36R interacts with IL-1RAcP even in the absence of an agonist.

34 xpression of ectodomain (ECD) of Il-1Rrp2 or IL-1RAcP exhibited dominant-negative effect on IL-36R si

35 R1) and the IL-1 receptor accessory protein (IL-1RAcP) form a functional IL-1 receptor complex that i

36 mRNA arises from alternative splicing of the IL-1RAcP gene (shown here to encompass 12 exons spanning

37 tallizable-linked construct to induce IL-36R.IL-1RAcP heterodimerization and predicted the binding af

38 L-36 receptor (IL-36R) and a shared subunit, IL-1RAcP (IL-1 receptor accessory protein).

39 e previously reported a novel isoform of the IL-1RAcP, IL-1RAcPb, found exclusively in CNS neurons.

40 logous to the requirement for both IL-1R and IL-1RAcP in IL-1-mediated responses.

41 We also provide evidence that IL-1RAcP, in addition to IL-1Rrp2, is required for signa

42 We conclude that 1) blocking IL-1RAcP inhibits IL-1 signaling in D10S cells, 2) domai

43 In mouse liver, IL-1RAcP is expressed as a soluble protein (sIL-1RAcP),

44 nvolved in complex formation with IL-1RI, 3) IL-1RAcP is not regulated as is IL-1RI in the same cells

45 Additionally, IL-1RAcP is required for IL-33-induced in vivo effects,

46 ine family, IL-1 receptor accessory protein (IL-1RAcP) is the co-receptor for eight receptor-cytokine

47 n the intracellular domain of membrane-bound IL-1RAcP (mIL-1RAcP).

48 Overexpression of an IL-1RAcP mutant lacking its intracellular domain, the IR

49 2, 3, and 4 recognized surface expression of IL-1RAcP on the Th2 D10S cells by FACS and inhibited IL-

50 of IL-1RI, but did not affect expression of IL-1RAcP or the proliferation of D10S cells.

51 Anti-IL-1RAcP-peptide 4, which targets the terminal segment o

52 The IL-1R accessory protein (IL-1RAcP) plays a role in IL-1R signaling by forming a c

53 ionally constrain the cognate receptor in an IL-1RAcP-receptive state.

54 33Ralpha (ST2L)/IL-1alpha accessory protein (IL-1RAcP) receptor that coordinates activation of ERK an

55 that IL-36Ra binds to IL-1Rrp2 and prevents IL-1RAcP recruitment and the formation of a functional s

56 Two alternatively spliced isoforms, soluble IL-1RAcP (sIL-1RAcP) and sIL-1RAcP-beta, which lack tran

57 Proportional expression of the different IL-1RAcP splice variants may be an important determinant

58 at the main pathway to the IL-36R.IL-36alpha.IL-1RAcP ternary complex is through the IL-36R.IL-36alph

59 ophilic peptide regions of the extracellular IL-1RAcP that may be available for complex formation (pe

60 and engaged identical molecular surfaces of IL-1RAcP, these cytokines had starkly different strategi

61 o IL-1RI to properly present the cytokine to IL-1RAcP, whereas IL-33 binds to ST2 in order to conform

62 the heterodimerization of IL-1 receptor and IL-1RAcP, whereas the intracellular TIR domain inhibits

63 rmalities that are dependent on IL-1Rrp2 and IL-1RAcP, which are two members of the IL-1R family.

64 te receptor, ST2, and the shared co-receptor IL-1RAcP, which we now present here.